SGLT2 Inhibitors and Cardiovascular Outcomes Trials: 4 Questions

Cardiovascular (CV) outcomes trials have generally shown that sodium–glucose cotransporter 2 inhibitors (SGLT2i) decrease CV risk in patients with type 2 diabetes mellitus (T2DM). Major CV outcomes randomized controlled trials (RCTs) for this class of drugs include:

• EMPA-REG OUTCOME: 7020 participants with T2DM at high CV risk randomized to empagliflozin or placebo; median follow-up of 3.1 years
• DECLARE-TIMI: 17 160 participants with T2DM at high CV risk randomized to dapagliflozin or placebo; median follow-up of 4.2 years
• CREDENCE: 4401 participants with T2DM and chronic kidney disease randomized to canagliflozin or placebo; median follow-up of 2.62 years
• CANVAS: 10 142 participants with T2DM at high CV risk randomized to canagliflozin or placebo; median follow-up of 3.6 years

Test your knowledge on the 4 major CV outcomes RCTs for SGLT2i with the 8-question quiz below.